{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:07:31Z","timestamp":1793956051142,"version":"4.8.0"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"20","funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology (DBT), Govt. of India","doi-asserted-by":"publisher","award":["BT\/PR15750\/MED\/29\/1015\/2016"],"award-info":[{"award-number":["BT\/PR15750\/MED\/29\/1015\/2016"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2021,1,14]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The challenges of viral infection have increased in recent decades due to the emergence of resistance, cross-resistance and drying up of antiviral drug discovery. Many neglected tropical viruses including the chikungunya virus, dengue virus &amp; Japanese encephalitis virus have gradually become global pathogens. This has further increased the burden of viral infection which necessitates the continuous development of antiviral therapy. The antiviral chemistry began with the development of thiosemicarbazide derived thiosemicarbazones as antiviral. Although very few thiosemicarbazides have progressed into clinical application, it still inspires antiviral development. During last 3 decades (1990- 2020), several efforts have been made to develop suitable antiviral by using thiosemicarbazide scaffold. Its hybridization with other pharmacophores has been used as a strategy to enhance safety and efficacy. Cyclization and substitution of thiosemicarbazides have also been used to develop potent antiviral. With the ability to form coordinate bonds, thiosemicarbazides have been used either as metal complex or chelator against viruses. This work is an attempt to systematically review the research on the use of thiosemicarbazides as an antiviral scaffold. It also reviews the structure-activity relationship and translational suitability of thiosemicarbazide derived compounds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1389557520666200818212408","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T03:29:17Z","timestamp":1597807757000},"page":"2135-2152","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Thiosemicarbazides: Updates on Antivirals Strategy"],"prefix":"10.2174","volume":"20","author":[{"given":"Alok Kumar","family":"Moharana","sequence":"first","affiliation":[{"name":"Drug Development and Analysis Laboratory, School of Pharmaceutical Sciences, Siksha \u2018O\u2019 Anusandhan (Deemed to be University), Bhubaneswar-751029, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudra Narayan","family":"Dash","sequence":"additional","affiliation":[{"name":"Drug Development and Analysis Laboratory, School of Pharmaceutical Sciences, Siksha \u2018O\u2019 Anusandhan (Deemed to be University), Bhubaneswar-751029, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2411-7292","authenticated-orcid":true,"given":"Bharat Bhusan","family":"Subudhi","sequence":"additional","affiliation":[{"name":"Drug Development and Analysis Laboratory, School of Pharmaceutical Sciences, Siksha \u2018O\u2019 Anusandhan (Deemed to be University), Bhubaneswar-751029, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-642-68487-6_5","author":"Pfau C.J.","year":"1982","unstructured":"Pfau C.J.; The thiosemicarbazones Chemotherapy of Viral Infections 1982,147-204","journal-title":"The thiosemicarbazones Chemotherapy of Viral Infections"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1749-6632.1965.tb12545.x PMID: 5323377","volume":"130","author":"Bauer D.J.","year":"1965","unstructured":"Bauer D.J.; Clinical experience with the antiviral drug marboran (1-methylisatin 3-thiosemicarbazone). Ann N Y Acad Sci 1965,130(1),110-117","journal-title":"Ann N Y Acad Sci"},{"key":"ref=3","first-page":"4661","volume":"2","author":"Singhal S.","year":"2013","unstructured":"Singhal S.; Arora S.; Agarwal S.; Sharma R.; Singhal N.; A review on potential biological activities of thiosemicarbazides. World J Pharm Pharm Sci 2013,2,4661-4681","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=4","first-page":"689","volume":"9","author":"Siddiqui E.J.","year":"2019","unstructured":"Siddiqui E.J.; Azad I.; Khan A.R.; Khan T.; Thiosemicarbazone complexes as versatile medicinal chemistry agents: A review. J Drug Deliv Ther 2019,9(3),689-703","journal-title":"J Drug Deliv Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0 PMID: 11259830","volume":"46","author":"Lipinski C.A.","year":"2001","unstructured":"Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001,46(1-3),3-26","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"Lipinski C.A.","year":"2004","unstructured":"Lipinski C.A.; Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004,1(4),337-341","journal-title":"Drug Discov Today Technol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1359-6446(03)02831-9 PMID: 14554012","volume":"8","author":"Congreve M.","year":"2003","unstructured":"Congreve M.; Carr R.; Murray C.; Jhoti H.A.; \u2018rule of three\u2019 for fragment-based lead discovery? Drug Discov Today 2003,8(19),876-877","journal-title":"Drug Discov Today"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2298\/JSC101217078V","volume":"76","author":"Vojinovic-Jesic L.S.","year":"2011","unstructured":"Vojinovic-Jesic L.S.; Leovac V.M.; Lalovic M.M.; Cesljevic V.I.; Jovanovic L.S.; Rodic M.V.; Divjakovic V.; Transition metal complexes with thiosemicarbazide-based ligands, Part 58. Synthesis, spectral and structural characterization of dioxovanadium (V) complexes with salicylaldehyde thiosemicarbazone. J Serb Chem Soc 2011,76(6),865-877","journal-title":"J Serb Chem Soc"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.14233\/ajchem.2013.OH105","volume":"25","author":"Shim J.","year":"2013","unstructured":"Shim J.; Jyothi N.R.; Farook N.M.; Biological applications of thiosemicarbazones and their metal complexes. Asian J Chem 2013,25(10),5838","journal-title":"Asian J Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3181\/00379727-73-17652","volume":"73","author":"Hamre D.","year":"1950","unstructured":"Hamre D.; Bernstein J.; Donovick R.; Activity of p-aminobenzaldehyde, 3-thiosemicarbazone on vaccinia virus in the chick embryo and in the mouse. Proc Soc Exp Biol Med 1950,73(2),275-278","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3181\/00379727-84-20690","volume":"84","author":"Thompson R.L.","year":"1953","unstructured":"Thompson R.L.; Davis J.; Russell P.B.; Hitchings G.H.; Effect of aliphatic oxime and isatin thisemicarbazones on vaccinia infection in the mouse and in the rabbit. Proc Soc Exp Biol Med 1953,84(2),496-499","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4049\/jimmunol.70.3.229","volume":"70","author":"Thompson R.L.","year":"1953","unstructured":"Thompson R.L.; Minton S.A.; Officer J.E.; Hitchings G.H.; Effect of heterocyclic and other thiosemicarbazones on vaccinia infection in the mouse. J Immunol 1953,70(3),229-234","journal-title":"J Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/1901167a0","volume":"190","author":"Bauer D.J.","year":"1961","unstructured":"Bauer D.J.; Sadler P.W.; Derivatives of isatin beta-thiosemicarbazone with anti-viral chemotherapeutic activity against ectromelia infection. Nature 1961,190(4782),1167-1169","journal-title":"Nature"},{"key":"ref=14","first-page":"17","volume":"18","author":"Tonew M.","year":"1974","unstructured":"Tonew M.; Tonew E.; Heinisch L.; Antiviral thiosemicarbazones and related compounds. 2. Antiviral action of substituted isatinisothiosemicarbazones. Acta Virol 1974,18(1),17-24","journal-title":"Acta Virol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1099\/0022-1317-67-8-1625","volume":"67","author":"Turk S.R.","year":"1986","unstructured":"Turk S.R.; Shipman C.; Drach J.C.; Structure-activity relationships among \u03b1-(N)-heterocyclic acyl thiosemicarbazones and related compounds as inhibitors of herpes simplex virus type 1-specified ribonucleoside diphosphate reductase. J Gen Virol 1986,67(Pt 8),1625-1632","journal-title":"J Gen Virol"},{"key":"ref=16","first-page":"879","volume":"1","author":"Smejkal F.","year":"1972","unstructured":"Smejkal F.; Budesinsky Z.; Sulka J.; Kuchar M.; Study of antiviral activity of some amantadine, pyrimidine, and isatine analogs. Adv Antimicrob Antineoplast Chemother 1972,1(2),879-883","journal-title":"Adv Antimicrob Antineoplast Chemother"},{"key":"ref=17","first-page":"31","volume":"28","author":"Iwasaki K.","year":"1955","unstructured":"Iwasaki K.; Nishimura T.; Igarashi Y.; Nagaki D.; Studies on the chemotherapy of influenza virus. I. Effect of thiosemicarbazones on influenza and Newcastle disease virus multiplication. Kitasato Arch Exp Med 1955,28(1-2),31-44","journal-title":"Kitasato Arch Exp Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/192341a0","volume":"192","author":"O\u2019Sullivan D.G.","year":"1961","unstructured":"O\u2019Sullivan D.G.; Sa Dler P.W.; Agents with high activity against type 2 poliovirus. Nature 1961,192(4800),341-343","journal-title":"Nature"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3181\/00379727-133-34528","volume":"133","author":"Brockman R.W.","year":"1970","unstructured":"Brockman R.W.; Sidwell R.W.; Arnett G.; Shaddix S.; Heterocyclic thiosemicarbazones: correlation between structure, inhibition of ribonucleotide reductase, and inhibition of DNA viruses. Proc Soc Exp Biol Med 1970,133(2),609-614","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1128\/AAC.19.4.682","volume":"19","author":"Shipman C.","year":"1981","unstructured":"Shipman C.; Smith S.H.; Drach J.C.; Klayman D.L.; Antiviral activity of 2-acetylpyridine thiosemicarbazones against herpes simplex virus. Antimicrob Agents Chemother 1981,19(4),682-685","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1749-6632.1977.tb21985.x PMID: 81642","volume":"284","author":"Levinson W.","year":"1977","unstructured":"Levinson W.; Rohde W.; Mikelens P.; Jackson J.; Antony A.; Ramakrishnan T.; Inactivation and inhibition of Rous sarcoma virus by copper-binding ligands: thiosemicarbazones, 8-hydroxyquinolines, and isonicotinic acid hydrazide. Ann N Y Acad Sci 1977,284,525-532","journal-title":"Ann N Y Acad Sci"},{"key":"ref=22","first-page":"105","volume":"36","author":"Bauer D.J.","year":"1955","unstructured":"Bauer D.J.; The antiviral and synergic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. Br J Exp Pathol 1955,36(1),105-114","journal-title":"Br J Exp Pathol"},{"key":"ref=23","first-page":"1051","volume":"26","author":"Polatnick J.","year":"1965","unstructured":"Polatnick J.; Effect of chemical agents on foot-and-mouth disease virus production in cell cultures. Am J Vet Res 1965,26(114),1051-1055","journal-title":"Am J Vet Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/221286b0","volume":"221","author":"Gladych J.M.Z.","year":"1969","unstructured":"Gladych J.M.Z.; Hunt J.H.; Jack D.; Haff R.F.; Boyle J.J.; Stewart R.C.; Ferlauto R.J.; Inhibition of rhinovirus by isatin thiosemicarbazone analogues. Nature 1969,221(5177),286-287","journal-title":"Nature"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1128\/AAC.31.11.1798","volume":"31","author":"Ronen D.","year":"1987","unstructured":"Ronen D.; Sherman L.; Bar-Nun S.; Teitz Y.; N-methylisatin-beta-4\u2032,4\u2032-diethylthiosemicarbazone, an inhibitor of Moloney leukemia virus protein production: Characterization and in vitro translation of viral mRNA. Antimicrob Agents Chemother 1987,31(11),1798-1802","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0232-4393(85)80007-X","volume":"140","author":"Singh S.P.","year":"1985","unstructured":"Singh S.P.; Awasthi L.P.; Thiosemicarbazides and triazole derivatives as potential antiviral agents. Zentralbl Mikrobiol 1985,140(2),155-159","journal-title":"Zentralbl Mikrobiol"},{"key":"ref=27","first-page":"7","volume":"6","author":"Bolsunova O.I.","year":"2017","unstructured":"Bolsunova O.I.; Zaika L.A.; Potopalsky A. I.; Voznyuk A.V.; Izatizon, as an izatin-thiosemicarbazone derivative, has antiviral, anti-tumor actions and no side effects. Int J Pharm Sci Inv 2017,6(5),7-9","journal-title":"Int J Pharm Sci Inv"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"20122","DOI":"10.1038\/srep20122","volume":"6","author":"Mishra P.","year":"2016","unstructured":"Mishra P.; Kumar A.; Mamidi P.; Kumar S.; Basantray I.; Saswat T.; Das I.; Nayak T.K.; Chattopadhyay S.; Subudhi B.B.; Chattopadhyay S.; Inhibition of chikungunya virus replication by 1-[(2-methylbenzimidazol-1-yl) methyl]-2-oxo-indolin-3-ylidene] amino] thiourea (MBZM-N-IBT). Sci Rep 2016,6,20122","journal-title":"Sci Rep"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"56165","DOI":"10.1155\/2007\/56165","volume":"2007","author":"Kovala-Demertzi D.","year":"2007","unstructured":"Kovala-Demertzi D.; Varadinova T.; Genova P.; Souza P.; Demertzis M.A.; Platinum (II) and palladium (II) complexes of pyridine-2-carbaldehyde thiosemicarbazone as alternative antiherpes simplex virus agents. Bioinorg Chem Appl 2007,2007,56165","journal-title":"Bioinorg Chem Appl"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/mol.110.069062","volume":"79","author":"Debebe Z.","year":"2011","unstructured":"Debebe Z.; Ammosova T.; Breuer D.; Lovejoy D.B.; Kalinowski D.S.; Kumar K.; Jerebtsova M.; Ray P.; Kashanchi F.; Gordeuk V.R.; Richardson D.R.; Nekhai S.; Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol 2011,79(1),185-196","journal-title":"Mol Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1080\/00397911.2019.1626893","volume":"49","author":"Abbas S.Y.","year":"2019","unstructured":"Abbas S.Y.; Basyouni W.M.; El-Bayouki K.A.; Dawood R.M.; Abdelhafez T.H.; Elawady M.K.; Efficient synthesis and anti-bovine viral diarrhea virus evaluation of 5 (aryldiazo) salicylaldehyde thiosemicarbazone derivatives. Synth Commun 2019,49(18),2411-2416","journal-title":"Synth Commun"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199808203390811 PMID: 9709051","volume":"339","author":"Breman J.G.","year":"1998","unstructured":"Breman J.G.; Henderson D.A.; Poxvirus dilemmas--monkeypox, smallpox, and biologic terrorism. N Engl J Med 1998,339(8),556-559","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005 PMID: 16048917","volume":"49","author":"Magee W.C.","year":"2005","unstructured":"Magee W.C.; Hostetler K.Y.; Evans D.H.; Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 2005,49(8),3153-3162","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1568005053174627","volume":"5","author":"Prichard M.N.","year":"2005","unstructured":"Prichard M.N.; Kern E.R.; Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord 2005,5(1),17-28","journal-title":"Curr Drug Targets Infect Disord"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.antiviral.2006.02.010","volume":"71","author":"Quenelle D.C.","year":"2006","unstructured":"Quenelle D.C.; Keith K.A.; Kern E.R.; In vitro and in vivo evaluation of isatin-\u03b2-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiviral Res 2006,71(1),24-30","journal-title":"Antiviral Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1021\/jm049147h","volume":"48","author":"Pirrung M.C.","year":"2005","unstructured":"Pirrung M.C.; Pansare S.V.; Sarma K.D.; Keith K.A.; Kern E.R.; Combinatorial optimization of isatin-\u03b2-thiosemicarbazones as anti-poxvirus agents. J Med Chem 2005,48(8),3045-3050","journal-title":"J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.antiviral.2012.02.012","volume":"94","author":"Prichard M.N.","year":"2012","unstructured":"Prichard M.N.; Kern E.R.; Orthopoxvirus targets for the development of new antiviral agents. Antiviral Res 2012,94(2),111-125","journal-title":"Antiviral Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.bmcl.2011.02.037","volume":"21","author":"Kang I.J.","year":"2011","unstructured":"Kang I.J.; Wang L.W.; Hsu T.A.; Yueh A.; Lee C.C.; Lee Y.C.; Lee C.Y.; Chao Y.S.; Shih S.R.; Chern J.H.; Isatin-\u03b2-thiosemicarbazones as potent herpes simplex virus inhibitors. Bioorg Med Chem Lett 2011,21(7),1948-1952","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1021\/ic0514492","volume":"45","author":"Cowley A.R.","year":"2006","unstructured":"Cowley A.R.; Dilworth J.R.; Donnelly P.S.; White J.M.; Copper complexes of thiosemicarbazone-pyridylhydrazine (THYNIC) hybrid ligands: A new versatile potential bifunctional chelator for copper radiopharmaceuticals. Inorg Chem 2006,45(2),496-498","journal-title":"Inorg Chem"},{"key":"ref=40","first-page":"87","volume":"45","author":"Varadinova T.","year":"2001","unstructured":"Varadinova T.; Kovala-Demertzi D.; Rupelieva M.; Demertzis M.; Genova P.; Antiviral activity of platinum (II) and palladium (II) complexes of pyridine-2-carbaldehyde thiosemicarbazone. Acta Virol 2001,45(2),87-94","journal-title":"Acta Virol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.taap.2004.02.006","volume":"197","author":"Genova P.","year":"2004","unstructured":"Genova P.; Varadinova T.; Matesanz A.I.; Marinova D.; Souza P.; Toxic effects of bis(thiosemicarbazone) compounds and its palladium(II) complexes on herpes simplex virus growth. Toxicol Appl Pharmacol 2004,197(2),107-112","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.4254\/wjh.v7.i5.725","volume":"7","author":"Barth H.","year":"2015","unstructured":"Barth H.; Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015,7(5),725-737","journal-title":"World J Hepatol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"Ghany M.G.","year":"2009","unstructured":"Ghany M.G.; Strader D.B.; Thomas D.L.; Seeff L.B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009,49(4),1335-1374","journal-title":"Hepatology"},{"key":"ref=44","author":"Altamura S.","year":"2003","unstructured":"Altamura S.; Koch U.; Treating hepatitis C viral infections with thiosemicarbazone compounds. US patent application US 10\/125,940 2003","journal-title":"US patent application US 10\/125,940"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.ejmech.2011.02.014 PMID: 21376429","volume":"46","author":"Kesel A.J.","year":"2011","unstructured":"Kesel A.J.; Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. Eur J Med Chem 2011,46(5),1656-1664","journal-title":"Eur J Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"138","DOI":"10.12991\/201317382","volume":"17","author":"\u00c7\u0131kla P.","year":"2013","unstructured":"\u00c7\u0131kla P.; Arora P.; Basu A.; Talele T.T.; Kaushik-Basu N.; K\u00fc\u00e7\u00fckg\u00fczel \u015e.G.; Etodolac Thiosemicarbazides: A novel class of hepatitis C virus NS5B polymerase inhibitors. Marmara Pharm J 2013,17(2),138-146","journal-title":"Marmara Pharm J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1039\/c0nj00061b","volume":"34","author":"Glisoni R.J.","year":"2010","unstructured":"Glisoni R.J.; Chiappetta D.A.; Finkielsztein L.M.; Moglioni A.G.; Sosnik A.; Self-aggregation behaviour of novel thiosemicarbazone drug candidates with potential antiviral activity. New J Chem 2010,34(9),2047-2058","journal-title":"New J Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ejps.2012.07.018","volume":"47","author":"Glisoni R.J.","year":"2012","unstructured":"Glisoni R.J.; Cuestas M.L.; Mathet V.L.; Oubi\u00f1a J.R.; Moglioni A.G.; Sosnik A.; Antiviral activity against the hepatitis C virus (HCV) of 1-indanone thiosemicarbazones and their inclusion complexes with hydroxypropyl-\u03b2-cyclodextrin. Eur J Pharm Sci 2012,47(3),596-603","journal-title":"Eur J Pharm Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1166\/jnn.2015.9613","volume":"15","author":"Glisoni R.J.","year":"2015","unstructured":"Glisoni R.J.; Castro E.F.; Cavallaro L.V.; Moglioni A.G.; Sosnik A.; Complexation of a 1-indanone thiosemicarbazone with hydroxypropyl-\u03b2-cyclodextrin enhances its activity against a hepatitis C virus surrogate model. J Nanosci Nanotechnol 2015,15(6),4224-4228","journal-title":"J Nanosci Nanotechnol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","volume":"59","author":"Pawlotsky J.M.","year":"2013","unstructured":"Pawlotsky J.M.; NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013,59(2),375-382","journal-title":"J Hepatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","volume":"59","author":"Zhan P.","year":"2016","unstructured":"Zhan P.; Pannecouque C.; De Clercq E.; Liu X.; Anti-HIV drug discovery and development: current innovations and future trends. Miniperspective J Med Chem 2016,59(7),2849-2878","journal-title":"Miniperspective J Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","volume":"10","author":"De Clercq E.","year":"2010","unstructured":"De Clercq E.; Antiretroviral drugs. Curr Opin Pharmacol 2010,10(5),507-515","journal-title":"Curr Opin Pharmacol"},{"key":"ref=53","first-page":"317","volume":"67","author":"De Clercq E.","year":"2013","unstructured":"De Clercq E.; The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS) Adv Pharmacol Academic Press 2013,67,317-358","journal-title":"The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS) Adv Pharmacol Academic Press"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5 PMID: 30193863","volume":"5","author":"Hamers R.L.","year":"2018","unstructured":"Hamers R.L.; Rinke de Wit T.F.; Holmes C.B.; HIV drug resistance in low-income and middle-income countries. Lancet HIV 2018,5(10),e588-e596","journal-title":"Lancet HIV"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMp1710608","volume":"377","author":"Beyrer C.","year":"2017","unstructured":"Beyrer C.; Pozniak A.; HIV drug resistance\u2014an emerging threat to epidemic control. N Engl J Med 2017,377(17),1605-1607","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/1521-4184(200205)335:5<183:AID-ARDP183>3.0.CO;2-U","volume":"335","author":"Mishra V.","year":"2002","unstructured":"Mishra V.; Pandeya S.N.; Pannecouque C.; Witvrouw M.; De Clercq E.; Anti-HIV activity of thiosemicarbazone and semicarbazone derivatives of (+\/-)-3-menthone. Arch Pharm (Weinheim) 2002,335(5),183-186","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1016\/j.bmcl.2005.07.046","volume":"15","author":"Bal T.R.","year":"2005","unstructured":"Bal T.R.; Anand B.; Yogeeswari P.; Sriram D.; Synthesis and evaluation of anti-HIV activity of isatin \u03b2-thiosemicarbazone derivatives. Bioorg Med Chem Lett 2005,15(20),4451-4455","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.1021\/jm1007616","volume":"53","author":"Pelosi G.","year":"2010","unstructured":"Pelosi G.; Bisceglie F.; Bignami F.; Ronzi P.; Schiavone P.; Re M.C.; Casoli C.; Pilotti E.; Antiretroviral activity of thiosemicarbazone metal complexes. J Med Chem 2010,53(24),8765-8769","journal-title":"J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1386-6532(00)00134-7 PMID: 11166657","volume":"20","author":"Gordeuk V.R.","year":"2001","unstructured":"Gordeuk V.R.; Delanghe J.R.; Langlois M.R.; Boelaert J.R.; Iron status and the outcome of HIV infection: an overview. J Clin Virol 2001,20(3),111-115","journal-title":"J Clin Virol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1365-2362.2002.0320s1091.x PMID: 11886438","volume":"32","author":"Georgiou N.A.","year":"2002","unstructured":"Georgiou N.A.; van der Bruggen T.; Oudshoorn M.; Hider R.C.; Marx J.J.M.; van Asbeck B.S.; Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. Eur J Clin Invest 2002,32(Suppl. 1),91-96","journal-title":"Eur J Clin Invest"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/j.jcv.2004.09.011","volume":"31","author":"Traor\u00e9 H.N.","year":"2004","unstructured":"Traor\u00e9 H.N.; Meyer D.; The effect of iron overload on in vitro HIV-1 infection. J Clin Virol 2004,31(Suppl. 1),S92-S98","journal-title":"J Clin Virol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e00365","DOI":"10.1128\/mBio.00365-13","volume":"4","author":"Taubenberger J.K.","year":"2013","unstructured":"Taubenberger J.K.; Morens D.M.; Influenza viruses: Breaking all the rules. MBio 2013,4(4),e00365-e13","journal-title":"MBio"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1056\/NEJMp0900648","volume":"360","author":"Moscona A.","year":"2009","unstructured":"Moscona A.; Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009,360(10),953-956","journal-title":"N Engl J Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/B978-0-12-405880-4.00006-8 PMID: 23886002","volume":"67","author":"van der Vries E.","year":"2013","unstructured":"van der Vries E.; Schutten M.; Fraaij P.; Boucher C.; Osterhaus A.; Influenza virus resistance to antiviral therapy. Adv Pharmacol 2013,67,217-246","journal-title":"Adv Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1021\/acs.jmedchem.6b01227","volume":"60","author":"Ju H.","year":"2017","unstructured":"Ju H.; Zhang J.; Huang B.; Kang D.; Huang B.; Liu X.; Zhan P.; Inhibitors of influenza virus Polymerase Acidic (PA) endonuclease: Contemporary developments and perspectives. J Med Chem 2017,60(9),3533-3551","journal-title":"J Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1016\/j.ejmech.2011.09.031","volume":"46","author":"Karak\u00fc\u00e7\u00fck-\u0130yido\u011fan A.","year":"2011","unstructured":"Karak\u00fc\u00e7\u00fck-\u0130yido\u011fan A.; Ta\u015fdemir D.; Oru\u00e7-Emre E.E.; Balzarini J.; Novel platinum(II) and palladium(II) complexes of thiosemicarbazones derived from 5-substitutedthiophene-2-carboxaldehydes and their antiviral and cytotoxic activities. Eur J Med Chem 2011,46(11),5616-5624","journal-title":"Eur J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00775-015-1292-0","volume":"20","author":"Rogolino D.","year":"2015","unstructured":"Rogolino D.; Bacchi A.; De Luca L.; Rispoli G.; Sechi M.; Stevaert A.; Naesens L.; Carcelli M.; Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease. J Biol Inorg Chem 2015,20(7),1109-1121","journal-title":"J Biol Inorg Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1286-4579(00)01320-4 PMID: 11113383","volume":"2","author":"Figueiredo L.T.M.","year":"2000","unstructured":"Figueiredo L.T.M.; The Brazilian flaviviruses. Microbes Infect 2000,2(13),1643-1649","journal-title":"Microbes Infect"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"470","DOI":"10.7476\/9788575413951","author":"Benchimol J.L.","year":"2001","unstructured":"Benchimol J.L.; Febre amarela: A doenca e a vacina, uma historia inacabada 2001,470","journal-title":"Febre amarela: A doenca e a vacina, uma historia inacabada"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/jmv.2078","volume":"65","author":"Vasconcelos P.F.","year":"2001","unstructured":"Vasconcelos P.F.; Costa Z.G.; Travassos Da Rosa E.S.; Luna E.; Rodrigues S.G.; Barros V.L.R.S.; Dias J.P.; Monteiro H.A.O.; Oliva O.F.P.; Vasconcelos H.B.; Oliveira R.C.; Sousa M.R.; Barbosa Da Silva J.; Cruz A.C.; Martins E.C.; Travassos Da Rosa J.F.; Epidemic of jungle yellow fever in Brazil, 2000: Implications of climatic alterations in disease spread. J Med Virol 2001,65(3),598-604","journal-title":"J Med Virol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.biopha.2016.12.112","volume":"87","author":"Pacca C.C.","year":"2017","unstructured":"Pacca C.C.; Marques R.E.; Espindola J.W.P.; Filho G.B.O.O.; Leite A.C.L.; Teixeira M.M.; Nogueira M.L.; Thiosemicarbazones and Phthalyl-Thiazoles compounds exert antiviral activity against yellow fever virus and Saint Louis encephalitis virus. Biomed Pharmacother 2017,87,381-387","journal-title":"Biomed Pharmacother"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1743-422X-5-64","volume":"5","author":"Sebastian L.","year":"2008","unstructured":"Sebastian L.; Desai A.; Shampur M.N.; Perumal Y.; Sriram D.; Vasanthapuram R.; N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo. Virol J 2008,5(1),64","journal-title":"Virol J"},{"key":"ref=73","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.20.30234 PMID: 27239817","volume":"21","author":"Nsoesie E.O.","year":"2016","unstructured":"Nsoesie E.O.; Kraemer M.U.; Golding N.; Pigott D.M.; Brady O.J.; Moyes C.L.; Johansson M.A.; Gething P.W.; Velayudhan R.; Khan K.; Hay S.I.; Brownstein J.S.; Global distribution and environmental suitability for chikungunya virus, 1952 to 2015. Euro Surveill 2016,21(20)","journal-title":"Euro Surveill"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/v10050235","volume":"10","author":"Subudhi B.B.","year":"2018","unstructured":"Subudhi B.B.; Chattopadhyay S.; Mishra P.; Kumar A.; Current strategies for inhibition of Chikungunya infection. Viruses 2018,10(5),235","journal-title":"Viruses"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1473-3099(01)00171-2 PMID: 11892494","volume":"2","author":"Guzm\u00e1n M.G.","year":"2002","unstructured":"Guzm\u00e1n M.G.; Kour\u00ed G.; Dengue: An update. Lancet Infect Dis 2002,2(1),33-42","journal-title":"Lancet Infect Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.antiviral.2018.12.016","volume":"163","author":"Lim S.P.","year":"2019","unstructured":"Lim S.P.; Dengue drug discovery: Progress, challenges and outlook. Antiviral Res 2019,163,156-178","journal-title":"Antiviral Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/jmv.24655","volume":"89","author":"Padmanabhan P.","year":"2017","unstructured":"Padmanabhan P.; Khaleefathullah S.; Kaveri K.; Palani G.; Ramanathan G.; Thennarasu S.; Tirichurapalli Sivagnanam U.; Antiviral activity of Thiosemicarbazones derived from \u03b1-amino acids against Dengue virus. J Med Virol 2017,89(3),546-552","journal-title":"J Med Virol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13065-018-0435-0","volume":"12","author":"Yusufzai S.K.","year":"2018","unstructured":"Yusufzai S.K.; Osman H.; Khan M.S.; Abd Razik B.M.; Ezzat M.O.; Mohamad S.; Sulaiman O.; Gansau J.A.; Parumasivam T.; 4-Thiazolidinone coumarin derivatives as two-component NS2B\/NS3 DENV flavivirus serine protease inhibitors: Synthesis, molecular docking, biological evaluation and structure-activity relationship studies. Chem Cent J 2018,12(1),69","journal-title":"Chem Cent J"},{"key":"ref=79","first-page":"149","volume":"8","author":"Mishra P.","year":"2016","unstructured":"Mishra P.; Subudhi B.B.; Molecular docking studies of MBZM-N-IBT on non-structural protein targets of Dengue virus. Der Pharma Chem 2016,8(16),149-153","journal-title":"Der Pharma Chem"},{"key":"ref=80","first-page":"739","author":"Fields N.B.","year":"1985","unstructured":"Fields N.B.; David M.K.; Robert M.C.; Joseph L.M.; Bernard R.; Robert E.S.; Fields Virology 1985,739-794","journal-title":"Fields Virology"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bmc.2015.12.008","volume":"24","author":"Cihan-\u00dcst\u00fcnda\u011f G.","year":"2016","unstructured":"Cihan-\u00dcst\u00fcnda\u011f G.; G\u00fcrsoy E.; Naesens L.; Ulusoy-G\u00fczeldemirci N.; \u00c7apan G.; Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones. Bioorg Med Chem 2016,24(2),240-246","journal-title":"Bioorg Med Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/v4102317","volume":"4","author":"Grant A.","year":"2012","unstructured":"Grant A.; Seregin A.; Huang C.; Kolokoltsova O.; Brasier A.; Peters C.; Paessler S.; Jun\u00edn virus pathogenesis and virus replication. Viruses 2012,4(10),2317-2339","journal-title":"Viruses"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/095632020301400205","volume":"14","author":"Garc\u00eda C.C.","year":"2003","unstructured":"Garc\u00eda C.C.; Brousse B.N.; Carlucci M.J.; Moglioni A.G.; Martins Alho M.; Moltrasio G.Y.; D\u2019Accorso N.B.; Damonte E.B.; Inhibitory effect of thiosemicarbazone derivatives on Junin virus replication in vitro. Antivir Chem Chemother 2003,14(2),99-105","journal-title":"Antivir Chem Chemother"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.ejmech.2007.10.023","volume":"43","author":"Finkielsztein L.M.","year":"2008","unstructured":"Finkielsztein L.M.; Castro E.F.; Fabi\u00e1n L.E.; Moltrasio G.Y.; Campos R.H.; Cavallaro L.V.; Moglioni A.G.; New 1-indanone thiosemicarbazone derivatives active against BVDV. Eur J Med Chem 2008,43(8),1767-1773","journal-title":"Eur J Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/v9060128","volume":"9","author":"Ye\u015filba\u011f K.","year":"2017","unstructured":"Ye\u015filba\u011f K.; Alpay G.; Becher P.; Variability and global distribution of subgenotypes of bovine viral diarrhea virus. Viruses 2017,9(6),128","journal-title":"Viruses"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0749-0720(15)30460-6","volume":"11","author":"Baker J.C.","year":"1995","unstructured":"Baker J.C.; The clinical manifestations of bovine viral diarrhea infection. Vet Clin North Am Food Anim Pract 1995,11(3),425-445","journal-title":"Vet Clin North Am Food Anim Pract"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/pathogens7010014","volume":"7","author":"Reichel M.P.","year":"2018","unstructured":"Reichel M.P.; Lanyon S.R.; Hill F.I.; perspectives on current challenges and opportunities for bovine viral diarrhoea virus eradication in australia and new zealand. Pathogens 2018,7(1),14","journal-title":"Pathogens"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1128\/JVI.00859-10","volume":"85","author":"Castro E.F.","year":"2011","unstructured":"Castro E.F.; Fabian L.E.; Caputto M.E.; Gagey D.; Finkielsztein L.M.; Moltrasio G.Y.; Moglioni A.G.; Campos R.H.; Cavallaro L.V.; Inhibition of bovine viral diarrhea virus RNA synthesis by thiosemicarbazone derived from 5,6-dimethoxy-1-indanone. J Virol 2011,85(11),5436-5445","journal-title":"J Virol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1016\/j.bmc.2017.05.056","volume":"25","author":"Soraires Santacruz M.C.","year":"2017","unstructured":"Soraires Santacruz M.C.; Fabiani M.; Castro E.F.; Cavallaro L.V.; Finkielsztein L.M.; Synthesis, antiviral evaluation and molecular docking studies of N4-aryl substituted\/unsubstituted thiosemicarbazones derived from 1-indanones as potent anti-bovine viral diarrhea virus agents. Bioorg Med Chem 2017,25(15),4055-4063","journal-title":"Bioorg Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1080\/00397911.2019.1626893","volume":"49","author":"Abbas S.Y.","year":"2019","unstructured":"Abbas S.Y.; Basyouni W.M.; El-Bayouki K.A.; Dawood R.M.; Abdelhafez T.H.; Elawady M.K.; Efficient synthesis and anti-bovine viral diarrhea virus evaluation of 5-(aryldiazo) salicylaldehyde thiosemicarbazone derivatives. Synth Commun 2019,49(18),2411-2416","journal-title":"Synth Commun"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2174\/187152607782110004","volume":"7","author":"Garc\u00eda C.C.","year":"2007","unstructured":"Garc\u00eda C.C.; Damonte E.B.; Zn finger containing proteins as targets for the control of viral infections. Infect Disord Drug Targets 2007,7(3),204-212","journal-title":"Infect Disord Drug Targets"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.5958\/0974-360X.2019.00337.8","volume":"12","author":"Mohapatra T.K.","year":"2019","unstructured":"Mohapatra T.K.; Subudhi B.B.; Repurposing of aspirin: Opportunities and challenges. Res J Pharm Tech 2019,12(4),2037-2044","journal-title":"Res J Pharm Tech"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.53879\/id.56.01.11469","volume":"56","author":"Swain R.P.","year":"2019","unstructured":"Swain R.P.; Subudhi B.B.; Amorphous solid dispersions of pioglitazone hydrochloride using cremophor rh 40 and poloxamer 188: In vitro and in vivo evaluation. Indian Drugs 2019,56(1),45-55","journal-title":"Indian Drugs"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"28","DOI":"10.53879\/id.55.07.11348","volume":"55","author":"Mohapatra T.K.","year":"2018","unstructured":"Mohapatra T.K.; Sarkar P.; Dash R.N.; Moharana A.K.; Subudhi B.B.; Evaluation of complementary effects of turmeric, ginger and cinnamon with aspirin. Indian Drugs 2018,55(7),28-35","journal-title":"Indian Drugs"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185046\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T19:39:18Z","timestamp":1696534758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185046\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":94,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,1,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557520666200818212408","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}